Cost effectiveness of different treatment strategies with natalizumab for pregnant women with multiple sclerosis.

ABSTRACT:

Background

The management of multiple sclerosis (MS) during pregnancy poses significant challenges. This study aimed to evaluate the cost-effectiveness of three natalizumab treatment strategies during pregnancy from the UK healthcare system's perspective.

Methods

A Markov model was developed to assess the health outcomes and costs associated with three treatment strategies: continuous natalizumab treatment throughout pregnancy, treatment until the first trimester followed by discontinuation, and discontinuation at conception with resumption post-pregnancy. The model incorporated data on relapse rates, disability progression, costs and quality-adjusted life years (QALYs). Sensitivity analyses were conducted.

Results

Continuing natalizumab throughout pregnancy was the m

SUBMITTER: Walbaum M 

PROVIDER: S-EPMC11706867 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature